Amarin Corp Plc (AMRN)

[stock_revealer]

Price Targets and Consensus...

August 2018 [Before REDUCE-IT study results]
H.C. Wainwright Analyst Price Target $10 for AMRN

September 2018 [After topline data of REDUCE-IT study]
H.C. Wainwright Analyst Price Target raised to $20 from $10 for AMRN
https://thefly.com/landingPageNews.php?id=2794991&headline=AMRN-Amarin-price-target-raised-to--from--at-HC-Wainwright

October 2018 [Expectation of favorable outcome from AHA Conference]
H.C. Wainwright Analyst Price Target raised to $31 from $20 for AMRN
https://www.smarteranalyst.com/analyst-insights/biotech-stocks/heres-analyst-boosted-price-target-amarin-amrn-stock/

November 2018 [After full results at AHA Conference and published in NEJM]
H.C. Wainwright Analyst Price Target raised to $51 from $31 for AMRN
https://www.smarteranalyst.com/analyst-insights/biotech-stocks/h-c-wainwright-sees-80-upside-potential-three-biotech-stocks/

Consensus based on 5 Analysts = $34.80
https://www.tipranks.com/stocks/amrn/price-target

Why would the price targets be raised every month?
Because material information has been released that changes cardiovascular care worldwide.

Buyout coming after price is $35+ per share in my humble opinion. [I think $80 would be the minimum for management to consider it]
The longer Big Pharma waits, the more expensive AMRN is going to be.
The suitor needs to strike while the iron is hotttt or pay more later! :)

And we all know Big Pharma wants a good deal. Hesitation could mean missing out, forever.